Yat Sun Or
2017
In 2017, Yat Sun Or earned a total compensation of $1.8M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 31% increase compared to previous year.
Compensation breakdown
Bonus | $121,255 |
---|---|
Non-Equity Incentive Plan | $48,700 |
Option Awards | $599,585 |
Salary | $400,975 |
Stock Awards | $574,369 |
Other | $18,551 |
Total | $1,763,435 |
Or received $599.6K in option awards, accounting for 34% of the total pay in 2017.
Or also received $121.3K in bonus, $48.7K in non-equity incentive plan, $401K in salary, $574.4K in stock awards and $18.6K in other compensation.
Rankings
In 2017, Yat Sun Or's compensation ranked 6,129th out of 14,666 executives tracked by ExecPay. In other words, Or earned more than 58.2% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,129 | 58th |
Manufacturing | 2,251 | 61st |
Chemicals And Allied Products | 711 | 66th |
Drugs | 548 | 68th |
Pharmaceutical Preparations | 430 | 68th |
Or's colleagues
We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2017.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019